X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (41844) 41844
Book Review (4888) 4888
Publication (4003) 4003
Newsletter (2071) 2071
Book Chapter (222) 222
Conference Proceeding (146) 146
Magazine Article (129) 129
Newspaper Article (63) 63
Book / eBook (40) 40
Dissertation (27) 27
Trade Publication Article (22) 22
Transcript (8) 8
Reference (5) 5
Web Resource (5) 5
Report (2) 2
Data Set (1) 1
Government Document (1) 1
Paper (1) 1
Presentation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (37842) 37842
humans (22442) 22442
animals (18253) 18253
protease inhibitors - pharmacology (11702) 11702
proteases (10101) 10101
protease inhibitors (9296) 9296
pharmacology & pharmacy (8801) 8801
biochemistry & molecular biology (8368) 8368
male (7877) 7877
female (5809) 5809
mice (5546) 5546
rats (5288) 5288
chemistry, medicinal (4159) 4159
amino acid sequence (3848) 3848
proteins (3803) 3803
protease (3719) 3719
research (3714) 3714
kinetics (3658) 3658
apoptosis (3618) 3618
molecular sequence data (3591) 3591
hiv infections - drug therapy (3372) 3372
analysis (3359) 3359
expression (3254) 3254
cell biology (3222) 3222
adult (3024) 3024
cells, cultured (3010) 3010
structure-activity relationship (2986) 2986
hiv (2970) 2970
hiv protease inhibitors - pharmacology (2834) 2834
cell line (2686) 2686
infectious diseases (2607) 2607
immunology (2550) 2550
microbiology (2501) 2501
models, molecular (2476) 2476
enzymes (2420) 2420
dose-response relationship, drug (2396) 2396
in-vitro (2393) 2393
activation (2347) 2347
apoptosis - drug effects (2235) 2235
hiv-1 - drug effects (2224) 2224
inhibitors (2217) 2217
middle aged (2214) 2214
virology (2166) 2166
substrate specificity (2119) 2119
enzyme inhibitors - pharmacology (2101) 2101
antiviral agents (2076) 2076
protease inhibitor (2031) 2031
health aspects (2004) 2004
protease inhibitors - chemistry (1998) 1998
cells (1977) 1977
drug design (1976) 1976
physiological aspects (1952) 1952
peptides (1939) 1939
aids/hiv (1937) 1937
mutation (1935) 1935
cancer (1907) 1907
time factors (1904) 1904
binding sites (1903) 1903
hydrogen-ion concentration (1902) 1902
article (1893) 1893
cell line, tumor (1849) 1849
oncology (1832) 1832
molecular weight (1707) 1707
molecular structure (1660) 1660
protein binding (1647) 1647
oligopeptides - pharmacology (1636) 1636
identification (1602) 1602
drug therapy (1598) 1598
purification (1586) 1586
cysteine proteinase inhibitors - pharmacology (1564) 1564
endopeptidases - metabolism (1543) 1543
anti-hiv agents - pharmacology (1539) 1539
pharmacology (1538) 1538
biophysics (1528) 1528
hiv infections - virology (1528) 1528
abridged index medicus (1525) 1525
multidisciplinary sciences (1513) 1513
inhibition (1499) 1499
in vitro techniques (1483) 1483
neurosciences (1480) 1480
biochemistry (1449) 1449
proteolysis (1425) 1425
chemistry, organic (1424) 1424
research article (1419) 1419
antiviral agents - pharmacology (1417) 1417
peptide hydrolases - metabolism (1413) 1413
hiv protease inhibitors - therapeutic use (1389) 1389
antiretroviral therapy (1350) 1350
in-vivo (1350) 1350
therapy (1350) 1350
infection (1346) 1346
rats, sprague-dawley (1346) 1346
serine proteinase inhibitors - pharmacology (1332) 1332
protease inhibitors - therapeutic use (1327) 1327
electrophoresis, polyacrylamide gel (1315) 1315
thrombin (1313) 1313
inflammation (1305) 1305
anti-hiv agents - therapeutic use (1303) 1303
drug therapy, combination (1300) 1300
drug interactions (1294) 1294
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (43486) 43486
Russian (202) 202
Japanese (171) 171
German (145) 145
French (113) 113
Spanish (96) 96
Chinese (52) 52
Polish (17) 17
Italian (11) 11
Portuguese (7) 7
Hungarian (5) 5
Dutch (4) 4
Czech (3) 3
Slovak (3) 3
Slovenian (3) 3
Ukrainian (3) 3
Norwegian (2) 2
Swedish (2) 2
Turkish (2) 2
Bulgarian (1) 1
Finnish (1) 1
Hebrew (1) 1
Romanian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Nucleic Acids Research, ISSN 0305-1048, 2016, Volume 44, Issue 1, pp. D343 - D350
Journal Article
Cancer Cell, ISSN 1535-6108, 09/2012, Volume 22, Issue 3, pp. 345 - 358
Bortezomib therapy has proven successful for the treatment of relapsed/refractory, relapsed, and newly diagnosed multiple myeloma (MM); however, dose-limiting... 
DEUBIQUITINATING ENZYME | INACTIVATION | PROTEIN | THERAPY | ONCOLOGY | MDM2 | DEGRADATION | MECHANISMS | HAUSP | CANCER | P53 REGULATION | CELL BIOLOGY | Thiophenes - therapeutic use | Apoptosis - drug effects | Humans | Molecular Sequence Data | Antineoplastic Agents - therapeutic use | Pyrazines - therapeutic use | Thalidomide - pharmacology | Boronic Acids - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Protease Inhibitors - pharmacology | Thalidomide - analogs & derivatives | Multiple Myeloma - drug therapy | Dexamethasone - pharmacology | Antineoplastic Agents - pharmacology | Drug Therapy, Combination | Multiple Myeloma - enzymology | Protease Inhibitors - therapeutic use | Proto-Oncogene Proteins c-mdm2 - metabolism | Ubiquitin Thiolesterase - antagonists & inhibitors | Bortezomib | Cyclin-Dependent Kinase Inhibitor p21 - antagonists & inhibitors | Thiophenes - pharmacology | Random Allocation | Mice, SCID | Ubiquitin Thiolesterase - genetics | Xenograft Model Antitumor Assays | Dexamethasone - therapeutic use | Multiple Myeloma - pathology | Animals | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Neovascularization, Pathologic - drug therapy | Cell Line, Tumor | Mice | Thalidomide - therapeutic use | Pyrazines - pharmacology | Ubiquitin-Specific Peptidase 7 | Boronic Acids - pharmacology | Drug Resistance, Neoplasm - drug effects | Medical colleges | Dexamethasone | Proteases | Analysis | Multiple myeloma | Lymphomas | Apoptosis | Index Medicus
Journal Article
Nature Medicine, ISSN 1078-8956, 12/2011, Volume 17, Issue 12, pp. 1636 - 1640
Ubiquitin-tagged substrates are degraded by the 26S proteasome, which is a multisubunit complex comprising a proteolytic 20S core particle capped by 19S... 
MEDICINE, RESEARCH & EXPERIMENTAL | APOPTOSIS | PHOSPHORYLATION | BIOCHEMISTRY & MOLECULAR BIOLOGY | BORTEZOMIB | 26S PROTEASOME | CELL-DEATH | P53 | CELL BIOLOGY | UBIQUITINATION | ROLES | DEGRADATION | EXPRESSION | Tumor Suppressor Protein p53 - antagonists & inhibitors | Humans | Ubiquitin - metabolism | Breast Neoplasms | Protease Inhibitors - pharmacology | Multiple Myeloma - drug therapy | Ubiquitination | Proteasome Endopeptidase Complex - drug effects | Microarray Analysis | Ubiquitin Thiolesterase - metabolism | Female | Antineoplastic Agents - pharmacology | Ubiquitin Thiolesterase - antagonists & inhibitors | Disease Models, Animal | Bortezomib | Tumor Suppressor Protein p53 - metabolism | bcl-2-Associated X Protein - metabolism | Carboxypeptidases - antagonists & inhibitors | Mice, SCID | Piperidones - pharmacology | Ubiquitin Thiolesterase - genetics | bcl-2-Associated X Protein - antagonists & inhibitors | Gene Expression Regulation, Enzymologic | Animals | Cell Line, Tumor | Carboxypeptidases - metabolism | Mice | Mice, Inbred BALB C | Proteasome Endopeptidase Complex - metabolism | Proteasome Inhibitors | Pyrazines - pharmacology | Apoptosis | Boronic Acids - pharmacology | Physiological aspects | Care and treatment | Research | Ubiquitin-proteasome system | Cancer | Proteins | Inhibitor drugs | Molecular biology | Index Medicus | Medical and Health Sciences | Medicin och hälsovetenskap
Journal Article
PLoS Pathogens, ISSN 1553-7366, 07/2012, Volume 8, Issue 7, pp. 22 - e1002832
Hepatitis C virus (HCV) infects over 170 million people worldwide and is the leading cause of chronic liver diseases, including cirrhosis, liver failure, and... 
WILD-TYPE | RAPID VIRAL RESPONSE | ENZYMATIC-ACTIVITIES | PRECLINICAL PROFILE | MICROBIOLOGY | HCV INFECTION | INTERFERON-ALPHA | VIROLOGY | IN-VIVO | GENOTYPE 1 INFECTION | ANTIVIRAL EFFICACY | SERINE-PROTEASE | PARASITOLOGY | Hepatitis C - drug therapy | Proline - metabolism | Humans | Hepacivirus - genetics | Structure-Activity Relationship | Antiviral Agents - metabolism | Protease Inhibitors - pharmacology | Indoles - metabolism | Viral Nonstructural Proteins - chemistry | Antiviral Agents - chemistry | Lactams - pharmacology | Proline - pharmacology | Indoles - pharmacology | Protease Inhibitors - therapeutic use | Oligopeptides - chemistry | Hepacivirus - drug effects | Protein Structure, Tertiary | Antiviral Agents - pharmacology | Proline - analogs & derivatives | Sulfonamides - chemistry | Models, Molecular | Protease Inhibitors - chemistry | Protease Inhibitors - metabolism | Oligopeptides - metabolism | Sulfonamides - pharmacology | Lactams - metabolism | Proline - chemistry | Drug Resistance, Viral - genetics | Hepatitis C - virology | Sulfonamides - metabolism | Oligopeptides - pharmacology | Viral Nonstructural Proteins - antagonists & inhibitors | Indoles - chemistry | Lactams - chemistry | Virus diseases | Viral drug resistance | Research | Protease inhibitors | Properties | Observations | Hepatitis | Liver cancer | Liver diseases | Ligands | Genetic diversity | Drug resistance | Pharmaceutical industry | Cancer therapies | Viral infections | Index Medicus
Journal Article
Nature, ISSN 0028-0836, 02/2016, Volume 530, Issue 7589, pp. 233 - 236
The proteasome is a multi-component protease complex responsible for regulating key processes such as the cell cycle and antigen presentation(1). Compounds... 
VISUALIZATION | FALCIPARUM MALARIA | MECHANISM | SPECIFICITY | ARTEMISININ RESISTANCE | MULTIDISCIPLINARY SCIENCES | VALIDATION | ELECTRON-MICROSCOPY | IDENTIFICATION | PARASITE | HUMAN 20S PROTEASOME | Plasmodium falciparum - enzymology | Plasmodium - enzymology | Plasmodium chabaudi - enzymology | Species Specificity | Humans | Proteasome Inhibitors - chemistry | Plasmodium - drug effects | Plasmodium falciparum - drug effects | Protein Subunits - metabolism | Dose-Response Relationship, Drug | Artemisinins - pharmacology | Plasmodium chabaudi - physiology | Drug Design | Plasmodium - growth & development | Female | Drug Resistance | Antimalarials - adverse effects | Catalytic Domain | Proteasome Inhibitors - pharmacology | Models, Molecular | Proteasome Endopeptidase Complex - chemistry | Proteasome Inhibitors - toxicity | Proteasome Inhibitors - adverse effects | Antimalarials - pharmacology | Cryoelectron Microscopy | Drug Synergism | Animals | Substrate Specificity - drug effects | Proteasome Endopeptidase Complex - ultrastructure | Antimalarials - chemistry | Plasmodium chabaudi - drug effects | Mice | Mice, Inbred BALB C | Protein Subunits - antagonists & inhibitors | Protein Subunits - chemistry | Antimalarials - toxicity | Enzyme Activation | Plasmodium falciparum - growth & development | Proteasome Endopeptidase Complex - metabolism | Ubiquitin-proteasome system | Plasmodium | Health aspects | Proteins | Malaria | Protease inhibitors | Proteases | Erythrocytes | Ligands | Parasites | Drug dosages | Index Medicus
Journal Article
British Journal of Clinical Pharmacology, ISSN 0306-5251, 09/2013, Volume 76, Issue 3, pp. 455 - 466
AimsThe anticoagulant rivaroxaban is an oral, direct Factor Xa inhibitor for the management of thromboembolic disorders. Metabolism and excretion involve... 
cytochrome | glycoprotein | rivaroxaban | drug interactions | healthy subjects | 450 | P-glycoprotein | Rivaroxaban | Healthy subjects | Cytochrome P450 | Drug interactions | BAY-59-7939 | SAFETY | PREVENTION | PHARMACODYNAMICS | cytochrome P450 | PROTEASE INHIBITORS | IN-VITRO | FACTOR-XA INHIBITOR | ERYTHROMYCIN | PHARMACOLOGY & PHARMACY | LIVER-MICROSOMES | Anticoagulants - administration & dosage | Cytochrome P-450 Enzyme Inhibitors | Erythromycin - pharmacology | Ketoconazole - administration & dosage | Humans | Middle Aged | Cytochrome P-450 Enzyme System - metabolism | Midazolam - administration & dosage | Substrate Specificity | Metabolic Clearance Rate | Thiophenes - administration & dosage | Ketoconazole - pharmacology | Enzyme Inhibitors - administration & dosage | Young Adult | Drug Interactions | Enzyme Inhibitors - pharmacokinetics | Clarithromycin - pharmacokinetics | Clarithromycin - administration & dosage | Adult | Morpholines - administration & dosage | Enzyme Inhibitors - pharmacology | Ketoconazole - pharmacokinetics | Midazolam - pharmacokinetics | Cytochrome P-450 CYP3A - administration & dosage | Erythromycin - administration & dosage | ATP Binding Cassette Transporter, Subfamily B, Member 1 - antagonists & inhibitors | ATP Binding Cassette Transporter, Subfamily B, Member 1 - metabolism | Thiophenes - pharmacokinetics | Erythromycin - pharmacokinetics | Cytochrome P-450 CYP3A - metabolism | Adolescent | Anticoagulants - pharmacokinetics | Morpholines - pharmacokinetics | Clarithromycin - pharmacology | Midazolam - pharmacology | Ketoconazole | Protease inhibitors | Fluconazole | Proteases | Cytochrome P-450 | Dosage and administration | Anticoagulants (Medicine) | Erythromycin | Thromboembolism | Index Medicus
Journal Article
Journal Article
Nature Chemical Biology, ISSN 1552-4450, 2014, Volume 10, Issue 8, pp. 656 - 663
Journal Article